Replication data for: The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India

Principal Investigator(s): View help for Principal Investigator(s) Mark Duggan; Craig Garthwaite; Aparajita Goyal

Name	File Type	Size	Last Modified
AER_2014_1301_Code.do	text/plain	26.3 KB	10/11/2019 10:36:PM
AER_2014_1301_Patent_Data.dta	application/octet-stream	12.9 MB	10/11/2019 10:36:PM
AER_2014_1301_README.pdf	application/pdf	38.3 KB	10/11/2019 10:36:PM
results_upload.log	text/plain	14.3 KB	10/11/2019 10:36:PM

Project Description

Summary: In 2005, as the result of a World Trade Organization mandate, India implemented a patent reform for pharmaceuticals that was intended to comply with the 1995 Trade-Related Aspects of Intellectual Property Rights (TRIPS). Exploiting variation in the timing of patent decisions, we estimate that a molecule receiving a patent experienced an average price increase of just 3-6 percent, with larger increases for more recently developed molecules and for those produced by just one firm when the patent system began. Our results also show little impact on quantities sold or on the number of pharmaceutical firms operating in the market. (JEL K33, L11, L13, L65, O14, O34, O38)

Scope of Project

JEL Classification:
      K33 International Law
      L11 Production, Pricing, and Market Structure; Size Distribution of Firms
      L13 Oligopoly and Other Imperfect Markets
      L65 Chemicals; Rubber; Drugs; Biotechnology; Plastics
      O14 Industrialization; Manufacturing and Service Industries; Choice of Technology
      O34 Intellectual Property and Intellectual Capital
      O38 Technological Change: Government Policy

Related Publications

Download this project

Published Versions

V1 [2019-10-12]

Export Metadata

Dublin Core

DDI 2.5

Report a Problem

Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.

This material is distributed exactly as it arrived from the data depositor. ICPSR has not checked or processed this material. Users should consult the investigator(s) if further information is desired.